{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-099856","form_type":"8-K","ticker":"CGTX","cik":"0001455365","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2023-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.984752+00:00","generated_at":"2026-06-10T20:50:29.030461+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Cognition Therapeutics provides pipeline update; SHINE interim shows 3-point ADAS-Cog benefit","bullets":["Cash and equivalents $37.2M as of June 30, 2023; expected runway through Q3 2024.","Total grant funding ~$171M; $81.8M remaining as of June 30, 2023.","SHINE Phase 2 interim (n=24) showed 3-point ADAS-Cog-11 difference at Day 185 vs placebo.","Topline data for SHINE (mild-moderate AD) and SHIMMER (DLB) expected mid-2024.","Phase 2 START (early AD) enrolling; MAGNIFY (dry AMD) in development."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-099856","json":"https://secwatch.observer/filing/0001104659-23-099856.json","markdown":"https://secwatch.observer/filing/0001104659-23-099856.md","text":"https://secwatch.observer/filing/0001104659-23-099856.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465923099856/0001104659-23-099856-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465923099856/tm2325877d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T20:50:29.030461+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}